Cardiex Limited (ASX:CDX) leverages its proprietary SphygmoCor® technology to develop and market vascular biomarker technologies and digital solutions focused on the world’s largest health disorders. SphygmoCor®, the company’s groundbreaking technology, has set the benchmark for noninvasive measurement of central aortic pressures and related arterial health characteristics, collectively referred to as…
Copper prices on the London Metal Exchange (LME) saw upward momentum in the first quarter of the year on…
Overview Impact Minerals (ASX:IPT) is an exploration and development mining company focused on discovering and developing new resource projects…
Victory Battery Metals CORP. (CSE:VR)(OTC PINK:VRCFF)(FWB:VR6) is pleased to announce that it has entered into an option agreement dated…
The first quarter of 2024 witnessed a surge in initial public offerings (IPOs) and mergers and acquisitions (M&A) within…
Overview Cardiex Limited (ASX:CDX) is an ASX-listed medical technology company leveraging its proprietary SphygmoCor® technology to develop and market…
Vizsla Copper Corp. (TSXV: VCU) (‘ Vizsla Copper ‘) and Universal Copper Ltd. (TSXV: UNV) (‘ Universal Copper ‘)…
(TheNewswire) Payment date for the distribution will be April 26, 2024 Coquitlam, BC TheNewswire – April 18, 2024 –…